<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01183559</url>
  </required_header>
  <id_info>
    <org_study_id>FCCC IRB 07-017</org_study_id>
    <nct_id>NCT01183559</nct_id>
    <nct_alias>NCT00462033</nct_alias>
  </id_info>
  <brief_title>A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery</brief_title>
  <official_title>Induction Therapy for Locally Advanced, Resectable Cancer of the Esophagus, Gastroesophageal (GE) Junction and Gastric Cancer: A Phase I Trial of ZD6474 (Zactima, Vandetanib), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the most tolerable and safe dose of ZD6474 (Zactima,&#xD;
      Vandetanib) when given with standard chemotherapy, radiation therapy and surgery in patients&#xD;
      with cancer of the esophagus&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidermal Growth Factor Receptor (EGFR) is known to be an important prognostic factor for&#xD;
      patients with esophageal cancer-overexpression is associated with a worse prognosis. Review&#xD;
      of the literature demonstrates presence of EGFR expression in up 90% of cases of esophageal&#xD;
      cancer. Additionally, Vascular Endothelial Growth factor (VEGF) is commonly overexpressed in&#xD;
      esophageal cancer (especially adenocarcinoma) and is linked to the transition from Barrett's&#xD;
      esophagus to invasive adenocarcinoma. Esophageal cancers with overexpression of VEGF are&#xD;
      associated with a worse prognosis and poorer response to conventional chemoradiation.&#xD;
&#xD;
      Therefore, we feel it would be valuable to add an inhibitor of EGFR and VEGFR to the therapy&#xD;
      of esophageal cancer to increase the rate of pathologic complete response and thus improve&#xD;
      overall survival. In current trials of ZD6474 in combination with chemotherapy, the dose has&#xD;
      been 300mg. We will perform a phase I trial in which we will dose-escalate ZD6474 to&#xD;
      determine if this drug is tolerable in combination with cytotoxic chemotherapy and external&#xD;
      beam radiation therapy. This would be the first trial in humans in which f these three&#xD;
      modalities would be combined. We will determine the maximum tolerated dose of ZD6474 in this&#xD;
      small trial and then hope to perform a larger phase II trial, perhaps in the context of the&#xD;
      Radiation Therapy Oncology Group (RTOG).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 7, 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of Vandetanib</measure>
    <time_frame>Within 4 weeks of initiation of chemo/radiation therapy</time_frame>
    <description>To determine the maximum tolerated dose (MTD) of Vandetanib given concurrently with chemotherapy and radiation therapy followed by surgery (esophagectomy)evaluated by the frequency, severity and duration of adverse events that occur during treatment and for four weeks following surgery as measured by serial blood tests, electrocardiograms and physical assessments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With Adverse Events</measure>
    <time_frame>Within 4 weeks of initiation of chemo/radiation therapy</time_frame>
    <description>To determine the safety and tolerability of Vandetanib when given in combination with chemotherapy and radiation therapy as evaluated by serial blood tests, electrocardiograms, and physical assessments during therapy and for four weeks following surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Cancer of the Esophagus</condition>
  <condition>Adenocarcinoma of the Gastroesophageal Junction</condition>
  <condition>Cancer of the Stomach</condition>
  <arm_group>
    <arm_group_label>Vandetanib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vandetanib 100 mg (6 patients) or 200 mg (3 patients) orally daily during the conventional 3D-guided conformal radiation therapy plus chemotherapy with carboplatin (AUC 5) on days 1 and 29, paclitaxel 50 mg/m2 i.v. weekly on days 1, 8, 15, 22, 29; and continuous infusion of 5-fluorouracil at 225 mg/m2 for 96 hours Monday-Friday during the radiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vandetanib</intervention_name>
    <description>Vandetanib 100mg orally escalating to doses of 200 mg daily 7 days a week until completion of radiation therapy</description>
    <arm_group_label>Vandetanib</arm_group_label>
    <other_name>ZD6474</other_name>
    <other_name>Zactima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 Fluorouracil (FU)</intervention_name>
    <description>5-FU 225 mg/m2/day continuous infusion over96 hours during radiation therapy</description>
    <arm_group_label>Vandetanib</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC=5 days 1 and 29 during radiation therapy</description>
    <arm_group_label>Vandetanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 50 mg/m2 days 1, 8, 15, 22, 29 during radiation therapy</description>
    <arm_group_label>Vandetanib</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiation Therapy (RT)</intervention_name>
    <description>External Beam Radiation Therapy(XRT)to a total dose of 4,500 centiGray (cGy) (180 cGy fractions daily) Monday through Friday for five weeks</description>
    <arm_group_label>Vandetanib</arm_group_label>
    <other_name>XRT</other_name>
    <other_name>RT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically documented carcinoma of the esophagus, gastroesophageal junction, or&#xD;
             stomach for which chemo/radiation therapy is appropriate.&#xD;
&#xD;
          -  Potentially resectable esophageal, Gastroesophageal junction carcinoma, or stomach&#xD;
             carcinoma&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status = 0-2&#xD;
&#xD;
          -  No evidence of distant metastases&#xD;
&#xD;
          -  Age 18 or greater&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Willingness to practice adequate contraception in women of childbearing potential&#xD;
             (WOCBP). Contraception must be continued for one month following discontinuation of&#xD;
             the study drugs. Females who are WOCBP must have negative pregnancy test within 7 days&#xD;
             of the first treatment. WOCBP includes any female who has experienced menarche and who&#xD;
             has not undergone successful surgical sterilization (hysterectomy, bilateral tubal&#xD;
             ligation, or bilateral oophorectomy) or is postmenopausal (defined as amenorrhea &gt;=12&#xD;
             consecutive months, or women on hormone replacement therapy (HRT) with documented&#xD;
             plasma follicle-stimulating hormone (FSH) level &gt;35 mIU/mL). Even women who are using&#xD;
             oral, implanted, or injectable contraceptive hormones or mechanical products&#xD;
             (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or&#xD;
             where partner is sterile (e.g. vasectomy), should be considered to be WOCBP. Should a&#xD;
             woman become pregnant or suspect she is pregnant while participating in this study,&#xD;
             she should inform her treating physician immediately.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Previous radiation therapy to chest or upper abdomen.&#xD;
&#xD;
          -  Evidence of severe or uncontrolled systemic disease or any concurrent condition which&#xD;
             in the Investigator's opinion makes it undesirable for the patient to participate in&#xD;
             the trial or which would jeopardize compliance with the protocol.&#xD;
&#xD;
          -  Impaired cardiac function at baseline, including any of the following:&#xD;
&#xD;
          -  Clinically significant cardiac event such as myocardial infarction; New York Heart&#xD;
             Association (NYHA) classification of heart disease &gt;2 within 3 months before&#xD;
             registration; or presence of cardiac disease that, in the opinion of the Investigator,&#xD;
             increases the risk of ventricular arrhythmia.&#xD;
&#xD;
          -  Inadequate pulmonary and cardiac function to tolerate surgery (see section 12): left&#xD;
             ventricular ejection fraction &lt;45% and/or a positive stress test; or Forced Expiratory&#xD;
             Volume (FEV1) of &lt;1.1 liters.&#xD;
&#xD;
          -  History of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy,&#xD;
             trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is&#xD;
             symptomatic or requires treatment or asymptomatic sustained ventricular tachycardia.&#xD;
             Atrial fibrillation, controlled on medication is not excluded.&#xD;
&#xD;
          -  Previous history of QTc prolongation as a result from other medication that required&#xD;
             discontinuation of that medication.&#xD;
&#xD;
          -  Congenital long QT syndrome, or 1st degree relative with unexplained sudden death&#xD;
             under 40 years of age.&#xD;
&#xD;
          -  Presence of left bundle branch block (LBBB).&#xD;
&#xD;
          -  QTc with Bazett's correction that is unmeasurable, or &gt;or= 480 msec on screening ECG.&#xD;
             If a patient has QTc &gt;or= 480 msec on screening ECG, the screen ECG may be repeated&#xD;
             twice (at least 24 hours apart). The average QTc from the three screening ECGs must be&#xD;
             &lt;480 msec in order for the patient to be eligible for the study).&#xD;
&#xD;
          -  Any concomitant medication that may cause QTc prolongation, induce Torsades de Pointes&#xD;
             or induce CYP3A4 function&#xD;
&#xD;
          -  Hypertension not controlled by medical therapy (systolic blood pressure greater than&#xD;
             160 mm Hg or diastolic blood pressure greater than 100 mm Hg)&#xD;
&#xD;
          -  Women who are currently pregnant or breast feeding.&#xD;
&#xD;
          -  Previous or current malignancies within the last 5 years, with the exception of&#xD;
             cervical carcinoma in situ and adequately treated basal cell or squamous cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
          -  Receipt of any investigational agents within 30 days prior to commencing study&#xD;
             treatment.&#xD;
&#xD;
          -  Uncontrollable diarrhea that may affect the ability of the patient to absorb ZD 6474&#xD;
             or tolerate side-effects.&#xD;
&#xD;
        Laboratory results:&#xD;
&#xD;
          -  Adequate bone marrow function as defined by granulocyte count &lt; 1500/mm^3 and platelet&#xD;
             count &lt; 100,000&#xD;
&#xD;
          -  Serum bilirubin &gt;1.5x the upper limit of reference range (ULRR)&#xD;
&#xD;
          -  Serum creatinine &gt;1.5 x ULRR or creatinine clearance &lt; 50 mL/minute (calculated by&#xD;
             Cockcroft-Gault formula.)&#xD;
&#xD;
          -  Potassium &lt; 4.0 mmol/L despite supplementation; serum calcium (ionized or adjusted for&#xD;
             albumin,) or magnesium out of normal range despite supplementation.&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &gt; 2.5 X ULRR&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Astsaturov,, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 13, 2010</study_first_submitted>
  <study_first_submitted_qc>August 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2010</study_first_posted>
  <results_first_submitted>August 26, 2011</results_first_submitted>
  <results_first_submitted_qc>January 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2021</results_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Details: Patients were accrued between March 2009 and August 2010 at Fox Chase Cancer Center outpatient medical oncology clinics.</recruitment_details>
      <pre_assignment_details>Resectable stage II-III esophageal and GE junction carcinomas;staging by CT and PET scans, endoscopic ultrasound. Patients with a history or presence of ventricular dysfunction, ventricular or atrial arrhythmias; heart block; congestive heart failure; recent myocardial infarction,unstable angina, or uncontrolled hypertension were excluded</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vandetanib</title>
          <description>All patients were treated with vandetanib with dose escalation from 100 mg (dose level 1) to 200 mg (dose level 2) orally daily for the duration of radiation therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vandetanib</title>
          <description>All patients were treated with vandetanib with dose escalation from 100 mg (dose level 1) to 200 mg (dose level 2) orally daily for the duration of radiation therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="35" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor site type</title>
          <description>Middle third, lower third, GE junction</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Middle third</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower third</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GE junction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Site of Disease</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Esophagus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastroesophageal junction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose of Vandetanib</title>
        <description>To determine the maximum tolerated dose (MTD) of Vandetanib given concurrently with chemotherapy and radiation therapy followed by surgery (esophagectomy)evaluated by the frequency, severity and duration of adverse events that occur during treatment and for four weeks following surgery as measured by serial blood tests, electrocardiograms and physical assessments</description>
        <time_frame>Within 4 weeks of initiation of chemo/radiation therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib</title>
            <description>All patients were treated with Vandetanib 100 mg QD (6 patients) or 200 mg daily (3 patients) orally daily during the conventional 3D-guided conformal radiation therapy plus chemotherapy with carboplatin (AUC 5) on days 1 and 29, paclitaxel 50 mg/m2 i.v. weekly on days 1, 8, 15, 22, 29; and continuous infusion of 5-fluorouracil at 225 mg/m2 for 96 hours Monday-Friday during the radiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose of Vandetanib</title>
          <description>To determine the maximum tolerated dose (MTD) of Vandetanib given concurrently with chemotherapy and radiation therapy followed by surgery (esophagectomy)evaluated by the frequency, severity and duration of adverse events that occur during treatment and for four weeks following surgery as measured by serial blood tests, electrocardiograms and physical assessments</description>
          <units>milligrams</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With Adverse Events</title>
        <description>To determine the safety and tolerability of Vandetanib when given in combination with chemotherapy and radiation therapy as evaluated by serial blood tests, electrocardiograms, and physical assessments during therapy and for four weeks following surgery</description>
        <time_frame>Within 4 weeks of initiation of chemo/radiation therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib</title>
            <description>All patients were treated with Vandetanib 100 mg QD (6 patients) or 200 mg QD (3 patients) orally daily during the conventional 3D-guided conformal radiation therapy plus chemotherapy with carboplatin (AUC 5) on days 1 and 29, paclitaxel 50 mg/m2 i.v. weekly on days 1, 8, 15, 22, 29; and continuous infusion of 5-fluorouracil at 225 mg/m2 for 96 hours Monday-Friday during the radiation.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Adverse Events</title>
          <description>To determine the safety and tolerability of Vandetanib when given in combination with chemotherapy and radiation therapy as evaluated by serial blood tests, electrocardiograms, and physical assessments during therapy and for four weeks following surgery</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From initiation of Vandetanib therapy through 6 months</time_frame>
      <desc>Adverse events evaluated for severity and relationship to therapy using a grading system in which Grade 3 = severe, Grade 4 = life-threatening or disabling and Grade 5 = death</desc>
      <group_list>
        <group group_id="E1">
          <title>Vandetanib</title>
          <description>All patients were treated with vandetanib with dose escalation from 100 mg (dose level 1) to 200 mg (dose level 2) orally daily for the duration of radiation therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic-enteric fistula</sub_title>
                <description>Grade 5</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain, upper abdomen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Stomach-Bronchial fistula</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT-SGPT</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>AST-SGPT</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Leukocyte, total WBC</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neutrophills, ANC/AGC</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sodium, serum low (hyponatremia)</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration, Depression</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study closed due to reaching the stated endpoint of determination of the phase II recommended and tolerated dose of Vandetanib</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Igor Astsaturov, MD, PhD, Assistant Professor, Medical Oncology</name_or_title>
      <organization>Igor Astsaturov, MD, PhD, Assistant Professor, Medical Oncology</organization>
      <phone>215 728-3135</phone>
      <email>Igor.Astsaturov@fccc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

